
This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease.

This cost-utility analysis compares the cost-effectiveness of salmeterol, fluticasone propionate, combination salmeterolfluticasone, and no maintenance therapy in chronic obstructive pulmonary disease.

Continuous home oxygen therapy for chronic obstructive pulmonary disease seems more cost-effective than other health technologies covered by Medicare, while nocturnal oxygen therapy is not.

Published: February 14th 2009 | Updated:

Published: April 2nd 2009 | Updated:

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
